Impurose A 20mg/75mg Capsule is a combination medication containing Rosuvastatin 20mg and Aspirin 75mg, indicated for the management of cardiovascular risk in patients with hyperlipidemia and those requiring antiplatelet therapy. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby aiding in the prevention of atherosclerosis and related cardiovascular events. Aspirin, a nonsteroidal anti-inflammatory drug with antiplatelet properties, irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and platelet aggregation, which helps prevent arterial thrombosis. The combination therapy is particularly beneficial in patients at high risk of myocardial infarction, stroke, or other thrombotic complications by addressing both lipid abnormalities and platelet activation. Impurose A should be administered under medical supervision, with dosage adjustments based on lipid profiles and bleeding risk. Caution is advised in patients with hepatic or renal impairment, bleeding disorders, or those on concurrent anticoagulant therapy. Regular monitoring of liver function tests, lipid levels, and signs of bleeding is recommended to optimize therapeutic outcomes and minimize adverse effects.